Peter W. Mason, PhD (adjunct)

Peter Mason is the Chief Technology Officer of Ervaxx, Ltd., in London, UK (2017-present). Prior to joining Ervaxx, Dr. Mason was the Executive Director of the Infectious Diseases Group at Regeneron Pharmaceuticals, Inc. in Tarrytown, NY (2014-2017). Despite his geographic distance from Texas, Dr. Mason has continued to maintain his affiliation with UTMB through the SIVS. In 2002, he joined the faculty at UTMB as a Professor of Pathology and a Senior Scientist in the Sealy Center for Vaccine Development (SCVD). His contributions to infectious disease research at UTMB included his co-invention of a new method to produce flavivirus vaccines (currently licensed to a pharmaceutical company and a veterinary company) and new methods to study flavivirus pathogenesis using single-cycle infectious particles.

Search PubMed for Dr. Mason's publications.